The pharmaceutical industry is urging the Office of U.S. Trade Representative to place Canada on its intellectual property “Priority Watch List” when the agency releases the 2014 edition of its Special 301 Report in April.
“Unfortunately, many of our trading partners do not respect the value of innovative medicines as demonstrated through limitations on the availability of pharmaceutical patents in places like India … or even Canada,” Jay Taylor, vice president of international advocacy for Big Pharma lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA), said at a USTR hearing in Washington, D.C., last week.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
